Kornitzer Capital Management INC Has Upped Its Portola Pharmaceuticals INC (PTLA) Stake by $4.71 Million

May 22, 2018 - By Vivian Park

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) LogoInvestors sentiment decreased to 1.36 in 2017 Q4. Its down 0.80, from 2.16 in 2017Q3. It dived, as 32 investors sold PTLA shares while 45 reduced holdings. 30 funds opened positions while 75 raised stakes. 56.35 million shares or 0.04% more from 56.33 million shares in 2017Q3 were reported. Sector Gamma As owns 50,000 shares for 0.41% of their portfolio. San Francisco Sentry Investment Grp (Ca) invested 0% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Jpmorgan Chase, a New York-based fund reported 650,264 shares. Aperio Group Inc Ltd Co reported 4,770 shares. Valley Natl Advisers holds 0.02% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) or 1,250 shares. Renaissance Tech Ltd Com owns 352,800 shares. Loring Wolcott & Coolidge Fiduciary Advsr Llp Ma reported 10 shares stake. Massachusetts-based Martingale Asset Mngmt Limited Partnership has invested 0% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Atika Mgmt Lc accumulated 70,000 shares. Mirae Asset Glob Invests Comm Limited stated it has 14,735 shares or 0.01% of all its holdings. Jane Street Ltd Liability Corporation holds 0% or 7,769 shares in its portfolio. Atwood And Palmer holds 1,450 shares. State Street Corp has invested 0.01% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Axa reported 0.02% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Meeder Asset holds 0% or 85 shares.

Since December 15, 2017, it had 0 insider purchases, and 2 sales for $607,613 activity. Wolff Henry Ward sold 12,000 shares worth $563,950.

Kornitzer Capital Management Inc increased its stake in Portola Pharmaceuticals Inc (PTLA) by 13.49% based on its latest 2017Q4 regulatory filing with the SEC. Kornitzer Capital Management Inc bought 98,215 shares as the company’s stock declined 43.57% with the market. The institutional investor held 826,027 shares of the health care company at the end of 2017Q4, valued at $40.21M, up from 727,812 at the end of the previous reported quarter. Kornitzer Capital Management Inc who had been investing in Portola Pharmaceuticals Inc for a number of months, seems to be bullish on the $2.70B market cap company. The stock decreased 0.99% or $0.41 during the last trading session, reaching $40.95. About 593,957 shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has declined 20.86% since May 22, 2017 and is downtrending. It has underperformed by 32.41% the S&P500.

Kornitzer Capital Management Inc, which manages about $11.35B and $5.88 billion US Long portfolio, decreased its stake in Akamai Technologies (NASDAQ:AKAM) by 151,265 shares to 344,989 shares, valued at $22.44M in 2017Q4, according to the filing. It also reduced its holding in Cavium Inc. (NASDAQ:CAVM) by 255,439 shares in the quarter, leaving it with 32,765 shares, and cut its stake in Class C (Non.

More notable recent Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) news were published by: Seekingalpha.com which released: “Buy Diamondback Energy On Declines – Cramer’s Lightning Round (5/11/18)” on May 14, 2018, also Fool.com with their article: “3 Small-Cap Biotech Stocks With Big Catalysts in May” published on April 30, 2018, Seekingalpha.com published: “Portola Pharmaceuticals’ (PTLA) CEO William Lis on Q1 2018 Results – Earnings Call Transcript” on May 15, 2018. More interesting news about Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) were released by: Fool.com and their article: “Portola Takes Another Big Step Forward” published on May 14, 2018 as well as Seekingalpha.com‘s news article titled: “Portola Pharmaceuticals: Elucidating The Ramifications Of The AndexXa Approval” with publication date: May 10, 2018.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Ratings Coverage

Among 6 analysts covering Portola Pharma (NASDAQ:PTLA), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Portola Pharma had 14 analyst reports since December 1, 2017 according to SRatingsIntel. The firm earned “Overweight” rating on Thursday, February 22 by Morgan Stanley. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) earned “Buy” rating by Oppenheimer on Wednesday, December 13. The company was maintained on Wednesday, February 21 by Credit Suisse. The firm has “Buy” rating given on Tuesday, March 13 by Oppenheimer. Credit Suisse maintained the shares of PTLA in report on Tuesday, March 13 with “Outperform” rating. Oppenheimer maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) rating on Thursday, May 17. Oppenheimer has “Buy” rating and $8000 target. The stock has “Buy” rating by Oppenheimer on Tuesday, December 19. As per Thursday, December 28, the company rating was maintained by Oppenheimer. Goldman Sachs initiated Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) rating on Friday, December 1. Goldman Sachs has “Buy” rating and $75.0 target. Morgan Stanley downgraded Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) on Thursday, March 1 to “Equal-Weight” rating.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.